Slim Family Increases ProKidney Stake to 36% via Major Share Conversion

Key Facts

The Slim family has increased its strategic stake in ProKidney Corp to 36% by holding over 73 million Class A shares, following a massive conversion to solidify voting power. In a new institutional development, Cormorant Asset Management disclosed a significant 9.71% passive stake in Bright Minds Biosciences Inc, holding 950,000 common shares through its Global Healthcare Master Fund. Parallel to this, Vanguard Group revealed new positions exceeding 5% in both Victoria's Secret & Co and Synaptics Inc, signaling robust interest in the retail and semiconductor sectors. Adding to the wave of shifts, a new filing was recorded for Arrowhead Pharmaceuticals, indicating fresh ownership movements. These activities, alongside recent positions in Veralto and Vertex Pharmaceuticals, underscore a broader trend of portfolio diversification by global asset managers. Analysts view the Slim family's consolidation and Cormorant's entry into biotech as strategic moves to secure long-term growth opportunities.